Sarepta Therapeutics Inc. (SRPT) Receives Outperform Rating from Robert W. Baird
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by analysts at Robert W. Baird in a report released on Monday. They presently have a $102.00 price objective on the stock. Robert W. Baird’s price objective would indicate a potential upside of 76.20% from the stock’s previous close.
Other research analysts also recently issued reports about the stock. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Jefferies Group set a $58.00 price target on shares of Sarepta Therapeutics and gave the company a “hold” rating in a report on Sunday, October 2nd. Wedbush raised their price target on shares of Sarepta Therapeutics from $66.00 to $72.00 and gave the company a “buy” rating in a report on Monday. William Blair upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Monday, September 19th. Finally, Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “sell” rating and set a $17.28 price objective on the stock in a research report on Tuesday, June 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $58.44.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 1.52% during mid-day trading on Monday, hitting $57.01. 653,633 shares of the company traded hands. The firm’s 50 day moving average price is $40.98 and its 200-day moving average price is $25.39. The stock’s market capitalization is $2.73 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $63.73.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-robert-w-baird-2.html
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the company earned ($0.87) EPS. On average, equities research analysts forecast that Sarepta Therapeutics will post ($4.23) EPS for the current year.
In other news, CEO Edward M. Md Kaye sold 40,179 shares of Sarepta Therapeutics stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the sale, the chief executive officer now owns 117,162 shares of the company’s stock, valued at approximately $7,029,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.
Large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its stake in shares of Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. acquired a new stake in Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC acquired a new stake in Sarepta Therapeutics during the second quarter valued at approximately $211,000. Finally, First Allied Advisory Services Inc. raised its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the last quarter. 65.29% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.